News

May 12, 2014
Nordic Bioscience A/S and Merck KGaA complete randomization of multi-center Phase 2b study of Sprifermin for Osteoarthritis of the knee earlier than planned.
Press Release, May 27, 2014
Nordic Bioscience Laboratory renews CAP accreditation